

Clinical & Translational Science Center Newsletter

September 2021

Letter from the Director



Dear Colleagues,

Our campus is alive with the footsteps and conversations of a new semester, and the CTSC is engaged in research efforts which will impact COVID-19 care and policy as well as improve the hospital environment.

Our Participant/Client Interactions (PCI) unit is supporting the local arm for Moderna's KidCOVE adolescent COVID-19 vaccine trial by enrolling and coordinating 60 participants. Like several adult COVID-19 vaccines, this vaccine is administered in two doses 28 days apart. This phase of the trial will enable investigators to determine the safest, most effective vaccine dose.

The Informatics Core is pulling the data for Dr. Yiliang Zhu's COVID-19 clinical treatment project, which will characterize clinical treatments of COVID-19 patients nationwide and related outcomes and also to help quantify the impact of various mitigation policies on containing the outbreak of COVID-19.

Finally, our Community Engaged Research Core (CERC) is working with surgeons Dr. Frances Alba and Dr. Joyce Pang to better understand how microaggressions impact the surgical environment. CERC is conducting and qualitatively analyzing interviews with OR surgeons, trainees, and staff to better understand the nature of harm microaggressions can cause in a surgical environment.

Every part of the CTSC is integral to our purpose and funding, and we aim to update each section of the CTSC newsletter monthly. Each PI has a personal, professional investment in the information we provide. Please submit that information to our team. The CTSC is here for your support.

The dedicated faculty, staff, and students at CTSC continue their research projects and look for innovative ways to support our communities. If you are interested in a rigorous quantitative rural research project focused on COVID-19, please contact me (RLarson@salud.unm.edu) to start a dialogue.

Masks are now required indoors for all individuals at the HSC. Stay abreast of the current policies by exploring the University's Bring Back the Pack COVID-19 guidance:

<https://bringbackthepack.unm.edu>.

The Health Sciences Center Office of Research website contains information on specific research-related updates (including the Research Continuity Guidelines for both [Laboratories & Research Facilities](#) and [Clinical Trial Research Faculty & Staff](#)) and can be accessed through the following link: <https://hsc.unm.edu/research/>.

All standard CTSC services are available. We encourage PIs to reach out to our Research Concierge (HSC-CTSCResearchConcierge@salud.unm.edu) with questions and/or to setup a consultation with the CTSC team.

If you have any questions about our assets and services, please contact the CTSC Research Concierge at HSC-CTSCResearchConcierge@salud.unm.edu. If you have any issues finding the information that you need, please reach out to [the CTSC Newsletter Team](#) and they will get back to you.

As always, thank you so much for your continued support of the Clinical & Translational Science Center!

Warm regards,

Richard S. Larson, MD, PhD

PI, CEO and Director, Clinical & Translational Science Center

CTSC Leadership

CTSC Director, CEO & Principal Investigator: Richard S. Larson, MD, PhD

Associate Director, CTSC: Matthew Campen, PhD

Associate Director, CTSC: Nancy Pandhi, MD, PhD, MPH

Chief Administrative Officer: Carla Cordova, MPH

Administrative Component Director: Beth Tigges, PhD, RN, PNP, BC

Tracking & Evaluation Module Lead: Beth Tigges, PhD, RN, PNP, BC

Quality & Efficiency Module Lead: Beth Tigges, PhD, RN, PNP, BC

Informatics Component Director: Christophe Lambert, PhD

Community & Collaboration Component Director: Mark Unruh, MD

Community Engagement Module Lead: Nancy Pandhi, MD, PhD, MPH

Collaboration and Commercialization Module Lead: Eric Prossnitz, PhD

Translational Endeavors (TE) Component Director: Christopher Abbott, MD

Translational Workforce Development (TWD) Module Lead: Karlett Parra, PhD

Pilot Translational & Clinical Studies (PTC) Module Lead: Corey Ford, MD, PhD

Research Methods (RM) Component Director: Mark Unruh, MD

Biostatistics, Epidemiology & Research Design (BERD) Module Lead: Mark Unruh, MD

Regulatory Knowledge & Support (RKS) Module Lead: Corey Ford, MD, PhD

Hub Research Capacity (HRC) Component Director: Nancy Pandhi, MD, PhD, MPH

Integration of Special Populations (ISP) Module Lead: Nancy Pandhi, MD, PhD, MPH

Participant Clinical Interactions (PCI) Director: Christopher Abbott, MD

Network Capacity (NC) Component Director: Hengameh Raissy, PharmD

Trial Innovation Network (TIN) Module Lead: Hengameh Raissy, PharmD

Drug Discovery & Repurposing Core Lead: TBD

Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD)

Module Lead: Kimberly Page, PhD, MPH

KL2 Mentored Career Development Component Director: Matt Campen, PhD

Clinical Laboratory Medical Director: Qian-Yun Zhang, MD, PhD

Featured Stories

PCI Recruiting for Juvenile COVID-19 Vaccine

During the past 18 months the world has been greatly impacted by the COVID-19 virus. The Participant Clinical Interactions Unit at CTSC has been able to play an integral part in the investigation of therapeutic medication for the treatment this virus. Now the PCI team is able to support researchers in the investigation of prevention of COVID-19 for children. Dr. Walter Dehority, associate professor in the Department of Pediatrics, is the local principal investigator for a Moderna vaccine trial.

Dr. Walter Dehority, along with his sub-investigators, Dr. Matthew Kadish, Dr. Hengameh Raissy and Dr. Chandler Todd are participating in the Moderna, Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age. This study will examine the safety and reactogenicity of mRNA-1273 vaccine administered in two doses 28 days apart.

The purpose of the KidCOVE study is to investigate the safety and effectiveness of the vaccine in children under the age of 12. The study design is utilizing a dose-escalation and age de-escalation design, along with a 3:1 ratio of the mRNA-1273 or placebo arm, this will enable investigators to determine which dosing level is the safest and most effective for children. As with some adult COVID vaccines, the Moderna mRNA-1273 is a messenger ribonucleic acid, which is an instructional molecule that naturally occurs in the body and tells cells how to make protein that can help the body's immune system protect itself from SARS-CoV-2.

The sponsor plans to enroll 4,000 participants in the 6 years to 12 years old age group, of which the HSC will enroll 60 participants with PCI providing full coordination support to the PI and his team.

For more information about PCI services, please contact the CTSC Research Concierge at:

HSC-CTSCResearchConcierge@salud.unm.edu.

CERC Analyzing Microaggressions in UNM Operating Rooms

Microaggressions are subtle, insulting comments or actions that can create hostility and foster an environment of disrespect. They can be in relation to a number of characteristics including gender, race, and sexual orientation. Previous studies with female surgeons and trainees have demonstrated that microaggressions exist at UNM. In an effort to better understand microaggressions in the operating room, Dr. Frances Alba, Associate Professor of Surgery in the Division of Urology and Dr. Joyce Pang, General Surgery Resident in the Department of Surgery, are conducting the "Gender Microaggression Experiences of Operating Room Staff and Male Surgeons" study, funded by an SRIA grant. The CERC team has completed 10 interviews with male surgeons and trainees, is in the process of conducting interviews with male and female OR staff to get their perspectives, and then will work

to qualitatively analyze and summarize both sets of interviews to better understand what microaggressions exist at UNM in the surgical environment.

Informatics Core Characterizes COVID-19 Treatments Nationwide

The CTSC Informatics Core has been utilizing the Cerner Learning Health Network (LHN) for more projects. Recently they pulled data for Dr. Yiliang Zhu's project "Integrating Data Across Heterogenous Systems in Pathway Modeling". The data will be used to characterize clinical treatments of COVID-19 patients nationwide and related outcomes and also to help quantify the impact of various mitigation polices on containing the outbreak of COVID19. Through the LHN they were able to pull the data he needed and, with the help of CTSC biostatisticians, complete the aggregate numbers needed to start analysis with other data sources. The Cerner LHN provides a rich data source for local and national COVID 19 data.

If you would like to know more, please contact Marguerite Valencia-Reed mvalencia-reed@salud.unm.edu or Harry Snow hsnow@slud.unm.edu for information.

Menu of Services & Resources

- [Biostatistics Support](#)
- [Brain & Behavioral Disorders](#)
- [Citing the Clinical & Translational Science Center](#)
- [Clinical Trials Participant Clinical Interactions](#)
- [Community Engagement](#)
- [Community Health Network](#)
- [Database Mining](#)
- [Drug Repurposing](#)
- [KL2 Scholars](#)
- [Intramural Funding](#)
- [Laboratory Services](#)
- [Pilot Funding](#)
- [Trial Innovation Network](#)
- [Quality & Efficiency](#)
- [Regulatory Knowledge & Support](#)
- [Rural Health Research](#)
- [Team Science & Commercialization](#)
- [Training](#)
- [Vulnerable Populations](#)

Administration

Tracking & Evaluation (T&E)

The Tracking and Evaluation Team is piloting a new "Common Metric" called the Median Accrual Metric. This metric is intended to look at our CTSC's ability to recruit and retain research participants. This metric will look at the entire calendar year for 2020 and will be reported in fall 2021.

Quality & Efficiency (Q&E)

The Quality and Efficiency Team continues to work on two specific process improvements initiatives. These two projects concluded in June of 2021 and will be evaluated for how the projects impacted our CTSC.

Community & Collaboration (C&C)

Team Science & Commercialization

CTSC promotes several events a year to promote Team Science and Commercialization- including both Hackathon and BioVenture. Promoting collaboration across academic disciplines, scientists can bring together ideas and fill in gaps to help move research out of the lab and into the market.

These events bring together clinicians, engineers, entrepreneurs, programmers, scientists, and students to form teams that worked to develop healthcare innovations and design a pitch allowed participants to practice skills necessary to begin the process of commercialization, a vital step to ensure technologies can reach patients.

For additional information and to register for upcoming Synergy meetings, please visit the webpage: <https://hsc.unm.edu/research/ctsc/programs/team-science.html>.

Find out more about ASCEND Hub resources and activities on the ASCEND Hub website: <https://ascendhub.org>.

Translational Endeavors (TE)i

Translational Workforce Development (TWD)

Translational Workforce Development has numerous [course offerings](#) and can even provide consultations as requested to assist you in your goals! Please request a [consultation](#) or additional information on any courses offered. The TWD team may be reached via HSC-CTSCTWDTraining@salud.unm.edu.

For information regarding TWD, please visit our webpage: <https://hsc.unm.edu/research/ctsc/training/index.html>.

Pilot Awards

The UNM Clinical & Translational Science Center (CTSC) is soliciting applications from all HS faculty members— senior as well as junior investigators— in response to the following pilot Request For Application.

We strongly encourage investigators to meet with the CTSC Research Concierge, HSC-CTSCResearchConcierge@salud.unm.edu, early in the planning and writing phases of their proposals in order to discuss CTSC resources required. If you have any questions please do not hesitate to contact Christina Anderson, CTSC Pilot Program Specialist, at ChAnderson@salud.unm.edu.

Pilot Award

As part of our CTSC award, NIH has identified the need to speed the movement of clinical research findings into the everyday practice of health care delivery. The purpose of this award is to support

pilot projects that utilize CTSC infrastructure to produce preliminary data for competitive NIH grant proposals in clinical and translational (T1, T2, T3, and T4) research.

Linking Clinical Trials to Drug Discovery and Repurposing Award

This RFA is a solicitation of applications from active CTSC investigators for projects that will link clinical research with drug discovery efforts in the Center for Molecular Discovery. The goal of this program is to: 1) develop cell-based assays for use in high-throughput screening, 2) to use these cell-based assays for the identification of drugs for clinical repurposing efforts, and 3) to utilize these previously FDA

CTSC/DCI Kidney Pilot Project Award

The CTSC, in conjunction with Dialysis Clinic, Inc. (DCI), are soliciting applications for pilot projects that will exemplify the CTSC mission of developing clinical and translational research with an emphasis on kidney disease, hypertension, and/or kidney transplantation. The purpose of this RFA is to support pilot projects that utilize the CTSC infrastructure to produce preliminary data for competitive NIH grant proposals in kidney disease, hypertension, and/or kidney transplantation clinical and translational (T1, T2, T3, and T4) research.

Innovation & Commercialization Award

The purpose of this RFA is to support innovative, high-risk/high-reward pilot projects to produce preliminary data for competitive NIH proposals in clinical and translational research. Most awards will be expected to seek NIH funding, most likely through an SBIR/STTR mechanism. These projects are intended to provide the preliminary data and initial corporate relationships to develop technology and move it towards successful commercialization.

Wicked Problems: Target Pilot Project Award

The National CTSA Network has identified a list of common and/or emerging problems (“wicked problems”) that require urgent scientific solution. The purpose of this RFA is to support pilot projects that tackle one of the targeted wicked problems listed below relating to data sharing and protection, big data, datasets or research collaboration:

- Data Sharing
- Big data to alter practice/diagnosis
- Use of multiple datasets
- Access to resources to address labor-intensive activities
- Privacy and data protection for research
- Removing institutional bottlenecks/sharing of resources
- Evaluating the impact of translational research efforts
- Implementing scientific review before studies are performed
- Dissemination and implementation Science
- EHR data integration
- Defining Impact for the CTSA Program
- Building a KL2 Scholar Community
- Addressing challenges in recruiting from rural sites
- Hub Stability

Research Methods (RM)

Biostatistics, Epidemiology, and Research Design (BERD)

Biostatistics Consultation Services Available at CTSC

The Biostatistics, Epidemiology, and Research Design (BERD) Core provides consultation and services, novel tools and methods intended to solve problems, and address barriers to the conduct of clinical and translational research. Services are open to all Health Sciences investigators (staff, students, and faculty) to understand the methodological aspects of their research for planning their projects, including power analysis, sample size, and research design for intermural and extramural grant submissions.

If you have a current pilot study that requires biostatistical support, please schedule appointments as soon as possible.

Are you interested in applying for a pilot study? It is strongly recommended that you make an appointment with one of our biostatisticians prior to your submission. Our expert biostatisticians can help in the initial stages of project development.

Appointments are available; but do fill up quickly. To schedule an appointment, please contact HSC-CTSCbiostats@salud.unm.edu. Services are offered Monday through Friday.

Please visit our web site: <http://hsc.unm.edu/research/ctsc/biostatistics/index.html>.

Regulatory Knowledge & Support (RKS)

The clinical research community is supported by the Federal Regulatory Support. This no cost service at the UNM HSC provides assistance with sponsor-investigator IND or IDE applications. This includes personal consultation and helpful templates through online modules on a range of topics related to FDA regulated studies. The goal is to provide the research community with the tools, training and support needed to navigate the complex regulatory pathways that accompany translational research. As part of this support, the UNM CTSC regulatory manager, Rebecca Brito, serves as a liaison to assist investigators in 4 key areas:

1. **Early Regulatory Strategy Development:** We encourage early interaction as a means to develop a regulatory strategy that is appropriate for the complexity of each research project.
2. **Regulatory Submissions and Maintenance:** We provide templates and consultation in preparation, submission, and maintenance of regulatory applications to the FDA.
3. **[ClinicalTrials.gov](#):** PRS administration that includes user account creation, maintenance, updates and consultation.
4. **Regulatory Education and Training:** We provide a variety of educational programs, including tailored educational seminars and recorded FDA webinars.

Assisting in these areas helps keep research studies on track and ensures a fluid process while developing each project. The goal of the UNM CTSC Regulatory Department is to help make each research project a success in translational science.

For more information on how we can help, please contact Rebecca Brito at rbrito@salud.unm.edu

Hub Research Capacity (HRC)

Integrating Special Populations (ISP)

The aim of the CTSC ISP team is to identify, develop, and deploy strategies to involve populations who are underserved or otherwise underrepresented in all stages of research. Urging investigators to design scientifically sound CTR that includes special populations from the outset is of critical importance. To aid investigators in these efforts, ISP has developed the new specialized Rurally Engaged, Spanish speaking or Network Specialized Experts (RESPONSE) team led by experienced faculty with mixed-methods CTR expertise. This group will provide pre-proposal consultations. Consultations will focus on best practices and considerations in New Mexico's special populations, and identify and connect investigators to potential engagement partners, collaborators, and UNM CTSC resources and services. The team coordinates closely with other CTSC cores (e.g., CERC, Translational Endeavors, KL2). Consults are currently available via web-based technology.

If you would like to request a consultation, please fill out the intake form at the following link.

<https://ctsctrials.health.unm.edu/redcap/surveys/?s=NNH84CWCAK>


For more information, please contact Jesus Fuentes at JEFuentes@salud.unm.edu

For more information about the Integrated Special Population team, please contact Dr. Nancy Pandhi, MD, PhD, MPH at NPandhi@salud.unm.edu.

For more information on Integrating Special Populations, please use the following link:

<https://hsc.unm.edu/research/ctsc/Community-Engaged-Research-Core/integrating-special-populations.html>

Community Health Specialist Disseminates Research Data to NM Health Councils



The Community Health Specialist (CHS), Cynthia Killough, continues to make connections with our neighboring communities in rural New Mexico. Cynthia has been attending 13 community health councils (currently virtually) around the state consistently over the past two years. These meetings provide a wealth of information about health disparities and concerns that are important to rural communities. The meetings also provide a way for Cynthia to introduce health research at UNM and help break down stigma associated with research in general.

Recently, we were able to give data back to two counties with the help of Heidi Rishel Brakey, on behalf of Dr. Julie Salvador, and Dr. Carla Wilhite. Cynthia helped promote both Principal Investigator's (PI) research projects in the past, in efforts to spread the word and recruit. Dr. Salvador is leading the Medicated Assisted Treatment (MAT) ECHO-F Model study (ongoing) and Dr. Wilhite led a New Mexico COVID-19 study. Cynthia and Heidi presented data from the MAT ECHO-F Study to the Lincoln County Health Council & Cynthia and Dr. Wilhite presented to the Otero County Health Council (both counties are depicted in the picture with gold stars). Cynthia hopes to encourage PIs to continue to disseminate data back to populations where we recruited from in efforts to continue to engage communities in health research.

Network Capacity (NC)

Trial Innovation Network (TIN)

The Trial Innovation Network is a collaborative initiative within the CTSA Program and is composed of three key partners: the CTSA Program Hubs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).

The vision for the Trial Innovation Network is to innovatively address critical roadblocks in clinical research and accelerate the translation of novel interventions into life-saving therapies.

The Trial Innovation Network is a collaborative national network with a focus in three main areas: operational innovation, operational excellence, and collaboration. The Trial Innovation Network will leverage the expertise and resources of the CTSA Program. The Trial Innovation Network will feature a single IRB system, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement.

The goal of the Trial Innovation Network is to not only execute trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand and innovate the process of conducting clinical trials.

The University of New Mexico CTSC has been a part of the Trial Innovation Network and as a result has been a participating site in several studies that impact a variety of disease states. This import work has helped connect physicians at the University of New Mexico with the clinical trials specific to their specialty. This effort has encouraged new investigators to become engaged in clinical research. This collaboration is part of the larger mission to move innovated research from the bench, to the bedside, and ultimately out into the communities in which we live.

For more information on the Trial Innovation Network, please contact George Garcia at gemgarcia@salud.unm.edu.

Drug Discovery & Repurposing Core (DDRC)

The DDRC is a Resource for Rapidly Translating Existing Drugs into New Clinical Trials

Do you have ideas about ways to repurpose existing FDA-approved drugs? The CTSC is here to help. The Drug Discovery and Repurposing Core DDRC collaborates with UNM investigators other CTSCs to improve health outcomes by providing unique resources for rapidly translating existing drugs for use in new clinical trials. DDRC provides access to and operation of state-of-the-art technology in drug rescue, repurposing, and repositioning through innovative tools that support investigators and start-up companies. Additionally, DDRC provides support and guidance in translating pilot projects from preclinical proof-of-principle to clinical proof-of-concept as well as helps to develop first-in-human clinical trials.

For additional information or to become a DDRC member, please visit the DDRC (formerly DR3N) webpage: <https://hsc.unm.edu/research/ctsc/dr3n/index.html>.

Clinical Laboratory (T-Laboratory)

Using CTSC Lab Services

The CTSC Translational Laboratory (T-Laboratory) is comprised of 6,000 square feet of wet-lab space, located in the newly renovated CTSC Building. The T-Laboratory offers state-of-the-art equipment and technical assistance with laboratory techniques for UNM HS investigators. The experienced staff of the T-Laboratory provide specialized laboratory support, customized to meet the needs of the investigators in all aspects of research including protocol/assay development, budget preparation, and testing of patient samples for various assays. The T-Laboratory provides sample preparation and technical support for other non-CTSC resources such as UNM Shared Flow Cytometry and High Throughput Screening Resource, and KUSAIR Small Animal Imaging. In addition, our staff will provide training to UNM HS investigators staff on molecular techniques, clinical techniques, or equipment. There are three options for utilization of CTSC T-Laboratory Services:

- Option A: Full Service Sample Testing
- Option B: Equipment Utilization by Investigator
- Option C: Preparation of Investigator's Experiments or Train Investigator's Staff to Perform Assays and Equipment.

Additionally, the CTSC Clinical Laboratory develops and carries out research-related sample analyses for UNM HS investigators, researchers throughout the United States and world, as well as corporate funded research projects.

For questions, please contact HSC-CTSCResearchConcierge@salud.unm.edu.

Funding Opportunities Specific to COVID-19

There are several significant funding opportunities available through the CTSC to address the COVID-19 pandemic. CTSC monitors these opportunities for our HSC faculty on a weekly basis and includes additional information from the NIH COVID-19 funding site for your convenience.

Some of these funding opportunities require an active grant or cooperative agreement. They may also need a Letter of Support from Dr. Larson, the CTSC PI. Please contact Michelle Parra (MMParra@salud.unm.edu) if you are interested in applying for any of the COVID-19 funding opportunities listed below.

Recent Active Funding Opportunities Specific to COVID-19 are listed below:

Title	Notice Number	Organization(s)	Release Date	RFA/PA/ PAR #	Expiry Date	Activity Code(s)
-------	---------------	-----------------	--------------	---------------	-------------	------------------

<p>Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</p>	<p>NOT-DA-21-041</p>	<p>NIDA</p>	<p>Apr 15, 2021</p>	<p>PA-20-272 PA-18-935 (Urgent Supplement)</p>	<p>Mar 31, 2022</p>	<p>333</p>
<p>Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs</p>	<p>NOT-TR-21-022</p>	<p>NCATS</p>	<p>Feb 26, 2021</p>	<p>PA-20-135</p>	<p>Aug 17, 2021</p>	<p>333</p>
<p>Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19)</p>	<p>NOT-GM-21-019</p>	<p>NIGMS</p>	<p>Feb 25, 2021</p>	<p>PA-18-935</p>	<p>Dec 16, 2021</p>	<p>333</p>

and the Causative Virus SARS-CoV-2						
Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders	NOT-DA-21-019	NIDA	Feb 10, 2021	PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146	Sep 8, 2024	R01, R03, R21
Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19	NOT-DA-21-017	NIDA	Feb 4, 2021	PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196	Sep 8, 2024	R01, R02, R03
Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)	NOT-AI-21-008	NIAID	Feb 4, 2021	PA-20-185 PA-20-195	Jan 8, 2023	R01, R21
Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV	NOT-DA-21-018	NIDA	Feb 3, 2021	PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146	Sep 8, 2024	R01, R03, R21

and Substance Use Disorders						
Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs	NOT-TR-21-017	NCATS	Feb 3, 2021	PA-20-272	Aug 17, 2024	333
Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)	NOT-DE-21-001	NIDCR	Jan 26, 2021	PA-20-185 PA-20-195	May 28, 2023	R01, R21
Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)	NOT-AG-21-015	NIA	Jan 26, 2021	PA-20-183 PA-20-184 PA-20-185 PA-20-200 PA-20-194 PA-20-196 PA-20-195 PAR-19-374 PAR-19-314 PAR-19-070 PAR-19-071 PAR-20-070	May 28, 2023	R01, R03, R21, U19, P01, R21/R33

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection	NOT-DA-21-011	NIDA	Jan 26, 2021	PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146	Sep 8, 2024	R01, R03, R21
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases	NOT-AR-21-012	NIAMS	Jan 5, 2021	PA-20-185 PA-20-195 PAR-21-055 PAR-21-054 PAR-21-053	Nov 19, 2021	R01, R02
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research	NOT-MH-21-120	NIMH	Dec 23, 2020	PA-20-272	Jun 2, 2023	333
Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities	NOT-MD-21-008	NIMHD , NIAID , NIAMS , NCI , ORWH , NIMH , NINR , OBSSR , ODP , NHLBI , NIDCR , SGMRO	Dec 17, 2020	PA-20-183 PA-20-185	Jan 8, 2022	R01

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection	NOT-DA-20-084	NIDA	Oct 27, 2020	PA-20-183 PA-20-200 PA-20-195	Sep 8, 2024	R01, R03, R21
Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)	RFA-DA-22-001	NIDA	Apr 27, 2021	R43/R44	Aug 14, 2021	R43/R44
Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	NOT-AI-20-065	NIAID	Aug 13, 2020	PAR-18-633	Sep 1, 2021	U01
Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	NOT-MD-20-025	NIMHD , NCI , NIDA , NLM , ODP , OBSSR , NIMH , NIAMS	Aug 13, 2020	PA-20-185	May 8, 2023	R01

<p>Notice of Special Interest (NOSI): Competitive Revision and Administrative Supplements to Existing NICHD HIV Grants and Cooperative Agreements to Understand HIV Health Impacts of COVID-19</p>	<p>NOT-HD-21-037</p>	<p>NICHD</p>	<p>Jul 2, 2021</p>	<p>PA-20-272 PA-18-935 NOT-OD-20-128 NOT-OD-20-118 NOT-OD-20-018</p>	<p>May 8, 2022</p>	<p>333</p>
<p>Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders</p>	<p>NOT-DC-20-008</p>	<p>NIDCD</p>	<p>Jun 4, 2020</p>	<p>PA-18-334 PA-20-185 PA-20-184 PA-20-196 PA-20-195 PA-19-270 PA-19-271 PA-19-273 PA-19-272</p>	<p>Sep 8, 2022</p>	<p>R01, R21, R41/R42, R43/R44</p>
<p>Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research</p>	<p>NOT-TR-20-017</p>	<p>NCATS</p>	<p>Apr 9, 2020</p>	<p>PA-20-135</p>	<p>Jan 26, 2022</p>	<p>333</p>

on the 2019 Novel Coronavirus						
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus	NOT-TR-20-016	NCATS	Apr 9, 2020	PA-18-591	Jan 26, 2022	333
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	PA-20-135	NIH, NCATS, NCCIH, NCI, NHGRI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINR, NLM, ORWH, OSC	Mar 10, 2020	PA-20-135	Sep 8, 2025	333
The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)	RFA-OD-19-029	ORWH, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIDA, NIDCR, NIEHS, NIMH, NINR	Sep 27, 2019	PA-20-272	Nov 27, 2021	R01
Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)	PAR-21-213	NIA, NIDA, ORWH, NIMH, NIAA, NIMHD, OBSSR, NEI	April 6, 2021	U01 Research Project (Cooperative Agreements)	Nov 9, 2021	U01

Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities	NOT-HD-21-038	NICHD	June 28, 2021	PA-20-200 , PA-21-221 , PA-20-195 , PA-20-194	May 8, 2024	R03, R21
Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide	NOT-AI-21-057	NIAID , NIMH , NID A	June 25, 2021	PA-20-185 , PA-20-195	May 8, 2024	R01, R21
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (\$10 Clinical Trial Not Allowed)	PAR-21-276	NIAID	Jul 16, 2021	Reissue of PAR-20-256	Jul 16, 2022	S10

If you are interested in applying for any of the grants, please email Michelle Parra (MMParra@salud.unm.edu).

For a full listing of COVID-19 through NIH, please access the following site:
<https://grants.nih.gov/grants/guide/COVID-Related.cfm>.

Citing the CTSC

When citing the CTSC, please be sure to include our Grant numbers:



Thank you!

HS in the News

For additional Health Sciences news, please visit:
<http://hscnews.unm.edu/>

News or corrections?

Please contact [the Newsletter Team](#).

The University Of New Mexico Mailing Address:
One University of New Mexico
MSC 08 4635
Albuquerque, NM 87131